Jamesf Markmann News Today

In people with type 1 diabetes, the body's immune system attacks and destroys insulin-producing β cells that control blood glucose levels and are part of a group of cells in the pancreas called pancreatic islets.

A new documentary, to be released June 24, shows the human side of islet cell transplantation research for type 1 diabetes and follows encouraging data presentations at two medical meetings.

Researchers at the American Diabetes Association Scientific Sessions reported that a patient with type 1 diabetes gained insulin independence after receiving an investigational stem cell-derived pancreatic islet cell therapy.

A second patient who received Vertexs VX-880 has experienced glycemic improvements, whereas the first one is completely insulin-independent.

NEW ORLEANS — A man with long-standing type 1 diabetes and no endogenous insulin production achieved insulin independence after an infusion of an investigational stem cell-derived pancreatic islet cell therapy, researchers reported.In a proof-of-concept study, treatment with half the target dose of VX-880 (Vertex Pharmaceuticals), a novel allogeneic stem cell-derived, fully differentiated,

But clinical trial currently under FDA hold as dosing is discussed

In type 1 diabetes, an autoimmune response attacks the pancreas's insulin-producing beta cells, leading to marked fluctuations in blood sugar levels. Lifelong daily insulin treatments are standard for patients, but replacing lost beta cells through transplants of islets, a group of cells in the pancreas, represents an attractive option.

/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...

/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System Panel votes unanimously in support of the OCS Liver Systems safety and effectiveness News provided by Share this article Share this article ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and...